Hot Life Science Investor Mandate 2: Hedge Fund Invests In PMA & 510(k) Devices and Diagnostics

1 Oct

A hedge fund with offices in New York and Miami looks to make 3-4 new equity investments into commercial-stage companies located from all geographies, however – the firm likes to see companies with commercial sales in North America and/or Europe. The firm cares less about company headquarters and more about where its products are approved and sold. For companies with enterprise values of $20M – $200M, the firm commits $5M – $20M and is willing to lead rounds or join syndicates as long as the investment gives a meaningful stake in the company for the purposes of being able to add value.

The fund is interested in medical devices and diagnostics. Within medical devices, the firm prefers devices with strong IP protection and generally with PMA or 510(k) approval. Within diagnostics, the firm is very opportunistic though their recent experience has focused on cancer genomic testing. The fund is open to all indication areas but historically has focused on cardiovascular, oncology and minimally invasive surgery.

The fund looks for seasoned management teams that have relevant experience in the sector the company is involved in. The firm likes to see this across the C-suite, particularly in the CEO and sales and marketing leadership. The firm takes a board seat when making investments and looks to add value through active involvement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: